Trials / Completed
CompletedNCT00116441
Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma
Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma: The Use of Autologous Tumor Cells With an Allogeneic GM-CSF Producing Cell Line
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 22 (planned)
- Sponsor
- Cell Genesys · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of vaccination with autologous myeloma cells and an allogeneic granulocyte-macrophage colony stimulating factor (GM-CSF) producing cell line.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Therapeutic Cellular Vaccine, GM-CSF Producing |
Timeline
- Start date
- 2000-10-01
- Completion
- 2004-10-01
- First posted
- 2005-06-30
- Last updated
- 2007-12-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00116441. Inclusion in this directory is not an endorsement.